<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report Pursuant to Section 13 or 15(d) of
the Securities Act of 1934
Date of Report (Date of earliest event reported): March 31, 2000
VEREX LABORATORIES, INC.
------------------------
(Exact name of registrant as specified in its charter)
COLORADO 0-11232 84-0850695
-------- ------- ----------
(State or other jurisdiction (Commission File No.) (IRS Employer ID No.)
of incorporation)
14 Inverness Drive East, D-100, Englewood, Colorado 80112
----------------------------------------------------------
(Address of principal executive office) (Zip Code)
Registrant's telephone number, including area code: (303) 799-4499
N/A
-------------------------------------------------------------
(Former name or former address, if changed since last report)
<PAGE>
<PAGE>
ITEM 1. CHANGES IN CONTROL OF REGISTRANT
Pursuant to a Stock Purchase and Subscription Agreement dated March 31,
2000 (the "SPA") among PR Pharmaceuticals, Inc. ("PRP") and Dr. James M. Dunn,
M.D and Carolyn K. Dunn, Jerry R. Dunn, James B. Petre, Birklea, Ltd., and
Glyn Mills, the majority shareholders of the Registrant, (collectively, the
"Majority Shareholders"), transferred their ownership in the common stock of
the Registrant - which comprised 52.95% of the Registrant's issued and
outstanding stock - to PRP in exchange for one (1) share of PRP common stock
for each fifteen (15) shares of the Registrant's common stock.
As a result of the transactions contemplated by the SPA, Dr. James M.
Dunn and Carolyn K. Dunn, Jerry R. Dunn, James B. Petre, Birklea, and Glyn
Mills have informed the Registrant that they are no longer deemed to
beneficially own any of the Registrant's Common Shares.
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
April 10, 2000 VEREX LABORATORIES, INC.
By: /s/ James M. Dunn, M.D.
James M.Dunn, M.D.
Its: President and CEO
